MedTrace Logo

Second Primary Cancers in Patients With Castration Resistant Prostate Cancer

NCT02702908 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6442

Last updated 2018-01-19

No results posted yet for this study

Summary

This study aims at estimating the incidence of second primary malignancies as well as the overall survival among metastasized prostate cancer (mPC) and metastasized castrate-resistant prostate cancer (mCRPC) patients not treated with radium-223-dichloride.

Conditions

  • Prostatic Neoplasms

Interventions

OTHER

Historical Reference group.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-15
Primary Completion
2017-10-20
Completion
2017-10-20

Countries

  • Germany

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02702908 on ClinicalTrials.gov